From: Adverse effects following COVID-19 vaccination in Iran
Variables | Groups | Number | Percent | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Age groups (years) | 18–30 | 527 | 11.04 | |||||||
31–40 | 679 | 14.22 | ||||||||
41–50 | 731 | 15.31 | ||||||||
51–60 | 534 | 11.18 | ||||||||
61–70 | 453 | 9.49 | ||||||||
70< | 1851 | 38.76 | ||||||||
Sex | Female | 2648 | 55.46 | |||||||
Male | 2127 | 44.54 | ||||||||
Vaccine | Sinopharm | 1564 | 32.75 | |||||||
AstraZeneca | 1460 | 30.58 | ||||||||
Sputnik V | 1751 | 36.67 | ||||||||
Job | Self Employed | 98 | 2.05 | |||||||
Retired | 1216 | 25.47 | ||||||||
Unemployed | 123 | 2.58 | ||||||||
Nurse | 386 | 8.08 | ||||||||
General practitioner | 217 | 4.54 | ||||||||
Specialist Doctor | 240 | 5.03 | ||||||||
Housewife | 958 | 20.06 | ||||||||
Student | 4 | 0.08 | ||||||||
Health staff | 480 | 10.05 | ||||||||
Health expert | 207 | 4.34 | ||||||||
Administrative staff | 846 | 17.72 | ||||||||
Education | Illiterate | 535 | 11.20 | |||||||
High school | 915 | 19.16 | ||||||||
Diploma | 852 | 17.84 | ||||||||
University degree | 2463 | 51.58 | ||||||||
Missing data | 10 | 0.21 | ||||||||
Underlying disease | Yes | 1525 | 31.9 | |||||||
No | 3250 | 68.1 | ||||||||
Previous COVID-19 infection | Yes | 1118 | 23.41 | |||||||
No | 3657 | 76.59 | ||||||||
Sensitive to substances | Nothing | 4426 | 92.7 | |||||||
Drug | 135 | 2.82 | ||||||||
Food | 202 | 4.23 | ||||||||
Drug and Food | 12 | 0.25 | ||||||||
Smoker | No | 4327 | 90.61 | |||||||
Yes | 444 | 9.29 | ||||||||
Missing data | 4 | 0.08 | ||||||||
Sedative use before and after vaccine | Before and after | 171 | 3.58 | |||||||
Before | 37 | 0.77 | ||||||||
After | 2163 | 45.29 | ||||||||
No sedative | 2402 | 50.30 | ||||||||
Missing data | 2 | 0.04 | ||||||||
Vaccinators informed participants about possible adverse effects | Yes | 3877 | 81.19 | |||||||
No | 898 | 18.81 | ||||||||
Sinopharm | 18–30 | 31–40 | 41–50 | 51–60 | 61–70 | > 70 | Male | Female | ||
Number | 28 | 33 | 37 | 31 | 190 | 1245 | 761 | 803 | ||
Percent | 0.02 | 0.02 | 0.02 | 0.02 | 0.12 | 0.80 | 0.49 | 0.51 | ||
AstraZeneca | 18–30 | 31–40 | 41–50 | 51–60 | 61–70 | > 70 | Male | Female | ||
Number | 266 | 284 | 161 | 67 | 141 | 541 | 702 | 758 | ||
Percent | 0.18 | 0.19 | 0.11 | 0.05 | 0.10 | 0.37 | 0.48 | 0.52 | ||
Sputnik V | 18–30 | 31–40 | 41–50 | 51–60 | 61–70 | > 70 | Male | Female | ||
Number | 233 | 362 | 533 | 436 | 122 | 65 | 664 | 1087 | ||
Percent | 0.13 | 0.21 | 0.30 | 0.25 | 0.07 | 0.04 | 0.38 | 0.62 |